Lindy Biosciences has developed a formulation platform that enables highly concentrated suspensions of proteins, allowing higher dosing in smaller volumes, ultimately allowing patients to self-administer biologics at home. Despite the industry pushing for more patient-centric care, many biologics must still be given in a clinical setting through lengthy IV infusions which are costly, inconvenient, and invasive. Ideally, these drugs would be given by a single subcutaneous injection that patients could administer themselves. However, antibodies often require higher doses than are currently possible in a subcutaneous injection, which is limited in volume. Lindy’s suspensions of highly concentrated proteins address these challenges, ultimately reducing the time patients spend taking medication. This improves patient compliance, decreases costs, and enables new high-dose molecules to reach the market. The typical method of addressing this challenge is to include additives in the formulation that decrease solution viscosity or increase molecular stability. However, these additives only offer minimal increases in product performance. By combining the stability of solid formulations and the beneficial properties of injectable suspensions, Lindy’s formulation platform can vastly improve the administration of therapeutic biologics. The company’s growing team includes expertise in biomaterials, drug delivery, bioprocessing, formulations, and technology commercialization. Lindy is currently working with 6 of the top 15 pharma companies in the world. The technology has been validated in preclinical models and has demonstrated good long-term stability. Lindy is currently raising capital to move into the clinic with multiple partners over the next two years.